Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors
- PMID: 10326706
- DOI: 10.1002/(sici)1097-0142(19990515)85:10<2255::aid-cncr22>3.3.co;2-4
Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors
Abstract
Background: Concerning malignant submandibular gland tumors, a rare disease entity, there are few recent reports of long term treatment results and of prognostic factors modifying these results.
Methods: The clinical data of 43 patients with malignant submandibular gland tumors who were treated at the Netherlands Cancer Institute between 1973 and 1994 were reviewed to evaluate treatment results and to control described prognostic factors. The median follow-up for patients alive at the end of follow-up was 143 months. Only univariate analyses were performed.
Results: The crude 5- and 10-year survival rates were 50% and 36%, respectively; the 5- and 10-year disease specific survival (DSS) rates were 61% and 51%, respectively; and the 5- and 10-year recurrence free percentages were 57% and 52%, respectively. Factors predicting crude survival were age at diagnosis (P = 0.0006), International Union Against Cancer/American Joint Committee on Cancer (UICC/ AJCC) TNM classification and its regrouping into tumor stage (P = 0.001), and clinical skin invasion (P = 0.005). In surgically treated patients, soft tissue invasion (P = 0.005), metastatic lymph nodes (P = 0.006), and perineural growth (P = 0.01) were prognostic for survival. Factors predicting DSS were the UICC/AJCC TNM classification and regrouping into tumor stage (P = 0.002). In surgical patients, perineural growth (P = 0.0008) conferred a lower DSS. Factors predicting tumor recurrence were the UICC/AJCC TNM classification and its regrouping into tumor stage (P = 0.009). In surgical patients, perineural growth (P = 0.003) predicts tumor recurrence.
Conclusions: Of patients with submandibular gland carcinoma treated according to a stable treatment protocol in a European tertiary referral center, 52% were tumor free 10 years later. Patients exhibiting the described adverse prognostic factors are likely to benefit from added radiotherapy.
Similar articles
-
Stage as major long term outcome predictor in minor salivary gland carcinoma.Cancer. 2000 Sep 15;89(6):1195-204. doi: 10.1002/1097-0142(20000915)89:6<1195::aid-cncr2>3.3.co;2-a. Cancer. 2000. PMID: 11002213
-
Prognostic factors and outcome analysis of submandibular gland cancer: a clinical audit.J Oral Maxillofac Surg. 2010 Sep;68(9):2104-10. doi: 10.1016/j.joms.2009.09.030. Epub 2010 Jun 11. J Oral Maxillofac Surg. 2010. PMID: 20538399
-
Survival in patients with submandibular gland carcinoma - Results of a multi-institutional retrospective study.Auris Nasus Larynx. 2018 Oct;45(5):1066-1072. doi: 10.1016/j.anl.2018.01.011. Epub 2018 Feb 7. Auris Nasus Larynx. 2018. PMID: 29428494
-
Malignant salivary gland tumors in Quito, Ecuador.ORL J Otorhinolaryngol Relat Spec. 2000 Nov-Dec;62(6):296-302. doi: 10.1159/000027772. ORL J Otorhinolaryngol Relat Spec. 2000. PMID: 11054011 Review.
-
Overview of resistance to systemic therapy in patients with breast cancer.Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1. Adv Exp Med Biol. 2007. PMID: 17993229 Review.
Cited by
-
Altered polymerase theta expression promotes chromosomal instability in salivary adenoid cystic carcinoma.J Cell Mol Med. 2022 Jul;26(14):3931-3949. doi: 10.1111/jcmm.17429. Epub 2022 Jun 21. J Cell Mol Med. 2022. PMID: 35726713 Free PMC article.
-
Timing of postoperative radiation therapy and survival in resected salivary gland cancers: Long-term results from a single institution.Oral Oncol. 2021 Dec;123:105626. doi: 10.1016/j.oraloncology.2021.105626. Epub 2021 Nov 19. Oral Oncol. 2021. PMID: 34801976 Free PMC article.
-
Epidemiology, outcomes, and prognostic factors in submandibular gland carcinomas: a national DAHANCA study.Eur Arch Otorhinolaryngol. 2023 Jul;280(7):3405-3413. doi: 10.1007/s00405-023-07940-y. Epub 2023 Apr 13. Eur Arch Otorhinolaryngol. 2023. PMID: 37052687 Free PMC article.
-
Development and characterization of xenograft model systems for adenoid cystic carcinoma.Lab Invest. 2011 Oct;91(10):1480-90. doi: 10.1038/labinvest.2011.105. Epub 2011 Jun 27. Lab Invest. 2011. PMID: 21709671 Free PMC article.
-
Inhibition of CDH11 Activates cGAS-STING by Stimulating Branched Chain Amino Acid Catabolism and Mitigates Lung Metastasis of Adenoid Cystic Carcinoma.Adv Sci (Weinh). 2025 Feb;12(8):e2408751. doi: 10.1002/advs.202408751. Epub 2024 Dec 31. Adv Sci (Weinh). 2025. PMID: 39739317 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources